Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial

Background and objective: Atomoxetine is a potent central norepinephrine uptake inhibitor, currently marketed for treatment of attention-deficit/hyperactivity disorder (ADHD). With the understanding that noradrenergic agents could be useful in assisting obese individuals to lose weight, we conducted...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International Journal of Obesity 2006-07, Vol.30 (7), p.1138-1142
Hauptverfasser:	Gadde, K.M, Yonish, G.M, Wagner, H.R. II, Foust, M.S, Allison, D.B
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adrenergic Uptake Inhibitors - adverse effects Adrenergic Uptake Inhibitors - therapeutic use Adult Anti-Obesity Agents - adverse effects Anti-Obesity Agents - therapeutic use atomoxetine Atomoxetine Hydrochloride Attention deficit hyperactivity disorder Biological and medical sciences blood glucose blood lipids Blood pressure Body Mass Index Body weight Clinical trials depression Diet dosage Double-Blind Method Drug dosages drug therapy drugs Epidemiology Feeding. Feeding behavior Female Fundamental and applied biological sciences. Psychology General aspects Health Promotion and Disease Prevention Heart rate Humans Internal Medicine Lipids Medical sciences Medicine Medicine & Public Health Metabolic Diseases Middle Aged noradrenergic agents Nutrition research Obesity Obesity - drug therapy Obesity - physiopathology original-article Propylamines - adverse effects Propylamines - therapeutic use Public Health Side effects Treatment Outcome Vertebrates: anatomy and physiology, studies on body, several organs or systems waist circumference Weight control weight loss Weight Loss - drug effects Women
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!